On January 5, 2024 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), reported that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week (Press release, Bexion, JAN 5, 2024, View Source [SID1234639005]). Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Date: Monday, January 8, 2024
Time: 3:00 pm PT
Location: Hilton San Francisco – Union Square
Track: Franciscan A (Ballroom Level)
Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference. Additionally, the Bexion management team will host one-on-one meetings with potential investors in San Francisco from January 8-11, 2024. If you would like to schedule a meeting, please reach out to the Company’s Investor Contact below.